VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Free Report) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

VNRX has been the topic of a number of other reports. HC Wainwright initiated coverage on shares of VolitionRx in a report on Tuesday, April 8th. They issued a "buy" rating and a $2.50 target price on the stock. D. Boral Capital restated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $3.33.

VolitionRx Price Performance

VolitionRx stock traded down $0.01 during trading hours on Wednesday, hitting $0.49. The stock had a trading volume of 158,762 shares, compared to its average volume of 175,041. The stock has a market capitalization of $49.58 million, a price-to-earnings ratio of -1.36 and a beta of 1.00. VolitionRx has a 1-year low of $0.42 and a 1-year high of $0.90. The stock's fifty day moving average is $0.52 and its two-hundred day moving average is $0.59.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds purchased 181,818 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the acquisition, the chief executive officer now owns 2,299,222 shares of the company's stock, valued at approximately $1,264,572.10. This represents a 8.59% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Northern Trust Corp raised its holdings in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after buying an additional 28,579 shares during the period. Two Sigma Securities LLC purchased a new position in VolitionRx in the fourth quarter valued at approximately $29,000. Millennium Management LLC purchased a new stake in shares of VolitionRx during the 4th quarter valued at about $36,000. Geode Capital Management LLC raised its holdings in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after buying an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. raised its holdings in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after buying an additional 1,481,000 shares during the period. Hedge funds and other institutional investors own 8.09% of the company's stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.